Ankit Mahadevia
CIK: 0001720974
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)3 (75.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (25.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SPRO
Spero Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 28, 2025SPRO
Spero Therapeutics, Inc.
Sale(S)Direct6.6K shares at avg. $1.97$13K - Jun 12, 2025SPRO
Spero Therapeutics, Inc.
Award(A)Direct20K shares- - Feb 5, 2025SPRO
Spero Therapeutics, Inc.
Sale(S)Direct14K shares at avg. $0.78$11K - Feb 5, 2025SPRO
Spero Therapeutics, Inc.
Sale(S)Direct55.3K shares at avg. $0.78$43K
1-4 of 4 transactions
About Mahadevia Ankit
Mahadevia Ankit (SEC CIK 0001720974) files insider reports with the SEC as Director of Spero Therapeutics, Inc. (SPRO).
Signal8 holds 3 ownership filings by Mahadevia Ankit, all Form 4s, filed between Feb 5, 2025 and Sep 3, 2025. Those filings report 4 transactions, from Feb 5, 2025 to Aug 28, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Mahadevia Ankit's filings is in CAMBRIDGE, MA.
Recent filings by Mahadevia Ankit
Other insiders filing for Spero Therapeutics, Inc. (SPRO)
- Zack Debra, Chief Medical Officer
- Deshpande Milind, Director
- Tregoning Kathleen, Director
- Smith Cynthia, Director
- VINK PATRICK V.J.J., Director
- THOMAS FRANK E, Director